JAK2 inhibitors: Are they the solution?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue SUPPL.1, 2011, Pages

  Santos, Fabio P S ^a   Verstovsek, Srdan ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Essential thrombocythemia; JAK2 inhibitor; JAK2 V617F; Myelofibrosis; Polycythemia vera

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; RUXOLITINIB; STAT5 PROTEIN; UNCLASSIFIED DRUG; XL 019;

ABDOMINAL PAIN; ANEMIA; BONE MARROW SUPPRESSION; CONFERENCE PAPER; CYTOPENIA; DIARRHEA; DISEASE ACTIVITY; FATIGUE; FORMICATION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HUMAN; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PANCREATITIS; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; SPLENOMEGALY; SYNCOPE; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

EID: 84860558297     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.02.007     Document Type: Conference Paper

References (81)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-8.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-97.
5. Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozy-gous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115:3589-97.
6. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66:11156-65.
7. Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hemato-poietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108:1652-60.
8. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010; 116:1528-38.
9. Marty C, Lacout C, Martin A, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010; 116:783-7.
10. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17:584-96.
11. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibro-sis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22:87-95.
12. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931-40.
13. Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycy-themia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107:4274-81.
14. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008; 111:5109-17.
15. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1:e18
16. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6:372-5.
17. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112:141-9.
18. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3:e270
19. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. NEngl JMed 2007; 356:459-68.
20. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116:988-92.
21. Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86:1603-7.
22. Giordanetto F, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002; 15:727-37.
23. Wilks AF, Harpur AG, Kurban RR, et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991; 11:2057-65.
24. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002; 277:47954-63.
25. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16:293-322.
26. Al-Shami A, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem 1999; 274:5333-8.
27. Bouscary D, Pene F, Claessens YE, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-43.
28. Mizuguchi R, Noto S, Yamada M, et al. Ras and signal transducer and activator of transcription (STAT) are essential and sufficient downstream components of Janus kinases in cell proliferation. Jpn J Cancer Res 2000; 91:527-33.
29. Winston LA, Hunter T. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 1995; 270:30837-40.
30. Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93:397-409.
31. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential forsignaling through a variety of cytokine receptors. Cell1998; 93:385-95.
32. Lindauer K, Loerting T, Liedl KR, et al. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001; 14:27-37.
33. Dusa A, Mouton C, Pecquet C, et al. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 2010; 5:e11157
34. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461:819-22.
35. Bannister AJ, Zegerman P, Partridge JF, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001; 410:120-4.
36. Lachner M, O'Carroll D, Rea S, et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001; 410:116-20.
37. Rinaldi CR, Rinaldi P, Alagia A, et al. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytc or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Blood 2010; 116:6023-6.
38. Scott LM, Scott MA, Campbell PJ, et al. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential throm-bocythemia. Blood 2006; 108:2435-7.
39. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106:631-5.
40. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombo-cythemia. Blood 2007; 110:840-6.
41. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential throm-bocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366:1945-53.
42. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential throm-bocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131:208-13.
43. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116:1205-10; quiz 387.
44. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110:4030-6.
45. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114:1477-83.
46. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-61.
47. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137:244-7.
48. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008; 112:844-7.
49. Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010; 120:2058-69.
50. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase my-eloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24:1713-8.
51. Pardanani AD, Gotlib JR, Jamieson C, et al. A Phase I evaluation of TG101348, a selective JAK2 Inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden [abstract]. Blood 2009; 114: Abstract 755.
52. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essen-tial thrombocythemia myelofibrosis. Blood 2010; 115:1131-6.
53. Verstovsek S, Kantarjian H, Mesa R, et al. Safety and efficacy of JAK1 & JAK2 inhibitor, INCB018424, in myelofibrosis. N Engl J Med 2010; 363:1117-27.
54. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryo-cytes to the biology of idiopathic myelofibrosis. Blood 2007; 110:986-93.
55. Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 2005; 105:464-73.
56. Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000; 157:15-9.
57. Schmitt A, Jouault H, Guichard J, et al. Pathologic interaction between megakaryo-cytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000; 96:1342-7.
58. Tefferi A, Kantarjian HM, Pardanani AD, et al. The clinical phenotype of myelo-fibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2 [abstract]. Blood 2008; 112:Abstract 2804.
59. Wang JC, Chen C, Lou LH, et al. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia 1997; 11:1827-32.
60. Jedidi A, Marty C, Oligo C, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009; 114:1842-51.
61. Vannucchi AM. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leuk Res 2009; 33:1581-3.
62. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: implications for the treatment of myelopro-liferative neoplasms. Blood 2010; 115:3109-17.
63. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-503.
64. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008; 13: 321-30.
65. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13:311-20.
66. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111:5663-71.
67. Hexner E, Goldberg JD, Prchal JT, et al. A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract]. Blood 2009; 114:Abstract 754.
68. Levis M, Ravandi F, Wang ES, et al. Results From a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse [abstract]. Blood 2009; 114:Abstract 788.
69. Goh KC, Ong WC, Hu C, et al. SB1518: A potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract]. Blood 2007; 110:Abstract 538.
70. Verstovsek S, Odenike O, Scott B, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis [abstract]. Blood, 2009; 114:Abstract 3905.
71. Seymour JF, To B, Goh A, et al. First Report of the rhase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis [abstract]. Haematologica 2010; 95 (suppl 2):Abstract 1444.
72. Verstovsek S, Pardanani AD, Shah NP, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. Blood 2007; 110:Abstract 553.
73. Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis [abstract]. Blood 2008; 112:Abstract 98.
74. Burns CJ, Bourke DG, Andrau L, et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett 2009; 19:5887-92.
75. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokinesin murine myelopro-liferative neoplasms. Blood 2010; 115:5232-40.
76. Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23:1441-5.
77. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16:487-97.
78. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea [abstract]. Blood 2009; 114:Abstract 311.
79. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocy-themia and polycythemia vera: result of a European Leukemia Net consensus conference. Blood 2009; 113:4829-33.
80. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418-24.
81. Moliterno AR, Hexner E, Roboz GJ, et al. An Open-Label Study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract]. Blood, 2009; 114:Abstract 753.